



Gene therapy and genome editing in ophthalmology: new Frontiers in the Treatment of Hereditary Retinal Dystrophies

GENE THERAPY AND GENOME EDITING IN OPHTHALMOLOGY: NEW FRONTIERS IN THE TREATMENT OF HEREDITARY RETINAL DYSTROPHIES

Author: Roberto Paione Gasparini

Postgraduate degree in Health and Development from the **Federal University of Mato Grosso do Sul.**

Medical Resident at the Federal University of São Paulo

SUMMARY

Hereditary retinal dystrophies (HRDs), which include Retinitis Pigmentosa and Leber Congenital Amaurosis, represent a heterogeneous group of rare and progressive diseases, frequently leading to irreversible blindness. Historically, therapeutic approaches were limited to symptomatic management and visual rehabilitation. However, the exponential advancement of genetics and molecular biology has revolutionized ophthalmology, introducing **gene therapy** as a promising curative modality. This scientific article aims to critically analyze and discuss the efficacy, challenges, and translational potential of gene replacement *and* genome editing (*CRISPR-Cas9*) therapies for monogenic HRDs. The methodology consists of an in-depth review of phase I/II and III clinical studies, with emphasis on the mechanism of action of adeno-associated viral vectors (AAVs) and the precision of CRISPR technology for *in vivo* mutation correction. Clinical results demonstrate that gene therapy, as exemplified by the use of voretigene neparvovec (*Luxturna*), can restore visual function in patients with specific mutations. However, regulatory challenges, vector immunogenicity, and the need for more efficient delivery systems for genome editing in dominant DHRs remain crucial barriers. It is concluded that ophthalmology is at the forefront of precision medicine, with the potential to transform incurable diseases into treatable conditions, requiring clinical ophthalmologists to master the principles of genomics.

Keywords: Ophthalmology. Hereditary Retinal Dystrophies. Gene Therapy. CRISPR-Cas9. Precision Medicine.



ABSTRACT

Hereditary Retinal Dystrophies (HRDs), including Retinitis Pigmentosa and Leber Congenital Amaurosis, represent a heterogeneous group of rare, progressive diseases often leading to irreversible blindness. Historically, therapeutic approaches were limited to symptomatic management and visual rehabilitation. However, the exponential advancement of genetics and molecular biology has revolutionized Ophthalmology, introducing **gene therapy** as a promising curative modality. This scientific article aims to critically analyze and discuss the efficacy, challenges, and translational potential of therapies based on gene replacement and genome editing (*CRISPR-Cas9*) for monogenic HRDs. The methodology consists of an in-depth review of phase I/II and III clinical trials, with emphasis on the mechanism of action of adeno-associated viral vectors (AAVs) and the precision of CRISPR technology for *in vivo* mutation correction. Clinical results demonstrate that gene therapy, as exemplified by the use of voretigene neparvovec (*Luxturna*), can restore visual function in patients with specific mutations. However, regulatory challenges, vector immunogenicity, and the need for more efficient delivery systems for genome editing in dominant HRDs remain crucial barriers. It is concluded that Ophthalmology is positioned at the forefront of precision medicine, with the potential to transform previously incurable diseases into treatable conditions, requiring the clinical ophthalmologist to master the principles of genomics.

Keywords: Ophthalmology. Hereditary Retinal Dystrophies. Gene Therapy. CRISPR-Cas9. Precision Medicine.

2. INTRODUCTION

Hereditary Retinal Dystrophies (HRDs) constitute a clinically diverse group of genetic retinopathies that share the common characteristic of progressive degeneration of photoreceptor cells (cones and rods) or the retinal pigment epithelium (RPE), culminating in severe visual loss or total blindness. It is estimated that HRDs affect more than two million individuals globally, representing a significant public health burden and a field of immense frustration for ophthalmologists and patients, given the historical absence of effective etiological treatments. The identification of more than 280 genes and thousands of mutations associated with these pathologies has confirmed the underlying molecular complexity, but simultaneously opened the door to **precision medicine** interventions aimed at correcting the root of the genetic problem.

This paradigm shift is moving the focus of ophthalmology from a purely rehabilitative approach to a curative one, centered on **gene therapy**.

The retina, with its immunologically privileged nature and anatomy easily accessible for subretinal and intravitreal injections, positioned itself as the ideal target and primary testing ground.



For gene therapy. The first regulatory approval for a gene therapy in DHR, voretigene neparvovec (*Luxturna*), in 2017, marked a watershed moment in the history of ophthalmology and gene therapy worldwide, demonstrating that correcting the mutation in the *RPE65* gene can restore visual cycle function. This initial clinical success spurred research into other mutations and the exploration of even more sophisticated genetic tools, such as **genome editing** through the CRISPR-Cas9 system. Such technologies offer the potential not only to *add* a correct gene (classical gene therapy), but to *correct* the defective gene at its native location in the genome, a promise particularly relevant for diseases caused by gain-of-function mutations (dominant DHRs).

The central challenge in translational research lies in overcoming biological and technical barriers, notably the need for more efficient and less immunogenic adeno-associated viral vectors (AAVs) capable of safely and specifically delivering genetic material (DNA or CRISPR components) to target cells (photoreceptors and RPE). Vector dosimetry, injection site (subretinal versus intravitreal), and host immune response are critical variables that determine treatment efficacy and safety. Furthermore, CRISPR-Cas9 technology, while promising, still faces issues related to cut specificity (*off-target effects*) and the need for a delivery system that ensures adequate penetration and expression of the editing system within the cell nucleus without inducing toxicity.

This article aims to provide the reader with a rigorous and up-to-date scientific analysis of the mechanisms of action, safety data, and clinical efficacy results of gene replacement therapy and genome editing approaches in the retina. The work focuses on the most recent advances, strategies for overcoming technical challenges, and the ethical and regulatory implications of this cutting-edge therapeutic modality. It is hoped that this review will serve as an essential guide for ophthalmologists seeking to integrate **genomic medicine** into their clinical practice, preparing for a future where hereditary vision loss will no longer be synonymous with an inevitably bleak prognosis, but rather an opportunity for curative and precise intervention.

3. Molecular Mechanisms of Hereditary Retinal Dystrophies and Their Therapeutic Targets

3.1. Genetic Complexity and Pathophysiology of Human Rehabilitation Disorders: From Mutation to Blindness

Hereditary Retinal Dystrophies (HRDs) are a remarkably heterogeneous set of conditions classified primarily by the affected gene, inheritance pattern (autosomal dominant, recessive, or X-linked), and the predominant cell type undergoing degeneration. The clinical spectrum ranges from Retinitis Pigmentosa (RP), characterized by initial loss of night vision.



(Nyctalopia) and subsequent narrowing of the visual field, leading to Leber Congenital Amaurosis (LCA), which manifests as blindness or severe visual dysfunction from birth. The central pathophysiology involves the malfunction or absence of essential proteins in the visual cycle (such as RPE65), in signal transduction (such as rhodopsin, *RHO*), or in the structural maintenance of photoreceptors and the RPE. The initial genetic mutation triggers a cascade of cellular events, including oxidative stress, apoptosis (programmed cell death), and chronic inflammation, leading to irreversible loss of sensory cells and visual function.

Elucidating the genetic basis of DHRs was crucial for defining therapeutic targets.

Mutations in the *RPE65* gene, for example, cause a deficiency in the enzyme needed to convert *all-trans* retinol into *11-cis* retinal in the RPE, essential for rhodopsin regeneration. This is a **loss -of-function mutation**, ideal for gene replacement therapy, as adding a functional copy of the gene corrects the enzymatic defect and restores the visual cycle. Mutations in genes like *RHO*, however, can cause dominant-pattern (gain-of-function) DHRs, where the mutant protein is toxic to the cell, requiring a **genome editing** approach to silence or correct the defective gene in its native location without adding new copies. The choice between replacement, silencing (RNA interference), or genome editing depends intrinsically on the type of mutation and the molecular mechanism of the disease.

The importance of **genetic identification** in the clinical practice of ophthalmologists has never been higher. With the advent of gene-specific therapies, clinical and electrophysiological diagnosis (electroretinogram) must be complemented by a genetic panel. Precise determination of the gene and mutation (genotyping) is a mandatory prerequisite for treatment eligibility, transforming the ophthalmologist into a manager of the patient's genomic information. This need has driven the creation of genetic diagnostic laboratories and genetic counseling platforms specializing in DHRs (Diagnosis Related to Hyperplasia). Knowledge of the rate of phenotypic progression associated with different genotypes (genotype-phenotype correlation) is crucial for defining the ideal "therapeutic window," that is, the moment when there are still enough viable cells to be rescued by therapy.

3.2. The Retina as an Ideal Therapeutic Target: Anatomical and Immunological Advantages

The retina, despite its histological complexity, offers unique advantages for the application of gene therapies compared to other organs. Its restricted and encapsulated anatomy allows the injection of low doses of viral vectors directly into the subretinal space (between the RPE and the photoreceptors) or into the vitreous cavity, ensuring high local drug concentration and minimizing systemic dispersion and toxicity to the rest of the body. The eye is considered an **immunologically privileged organ**, possessing active mechanisms to suppress the immune response. This is essential because the body tends to recognize adeno-associated viral vectors (AAVs), which are the main gene delivery vehicle, as pathogens, triggering an inflammatory response that can destroy the transfected cells.



The precision of subretinal delivery, achieved through pars plana vitrectomy and thin cannulation, allows direct access to the RPE and photoreceptors, cells that are the primary target in most retinal hemorrhagic diseases (RHDs). Although subretinal injection is surgically more invasive, it ensures greater specificity and less vector dilution. On the other hand, intravitreal injection, which is a simpler outpatient procedure, has been tested for RHDs affecting more superficial cells or for the delivery of new types of vectors with greater retinal penetration capacity. The choice of administration route is a central research topic and depends on the serotype (type) of the viral vector and the type of cell to be transfected, seeking maximum efficacy with minimum morbidity for the patient.

The sustainability of the therapeutic effect is another advantage of the retina. Photoreceptor and RPE cells are long-lived cells that do not replicate easily (quiescent cells). This means that once the therapeutic gene (transgene) is delivered and incorporated into the cell (transduction), it can be expressed for many years, offering the potential for **long-lasting** healing. or, at least, halting the progression of the disease. The demonstration of transgene expression for more than a decade in animal models and the prolonged follow-up of the first patients treated with gene therapy in humans support this promise. This permanence of gene expression is a key advantage of gene therapy compared to therapies based on proteins or small molecules, which require chronic and repetitive administration.

4. Adeno-associated viral vectors (AAVs) and gene replacement therapy

4.1. Architecture and Serotypes of AAVs: The Fundamental Vehicle of Ocular Gene Therapy

Adeno-associated viral vectors (AAVs) have established themselves as the vehicle of choice for ocular gene therapy due to their excellent safety profile and transduction efficacy in the retina. AAVs are non-pathogenic viruses that have the ability to infect human cells but do not cause serious disease. Most importantly, they are **non-replicating viruses**, as the viral genetic material is removed and replaced by the therapeutic gene (transgene). The vector architecture consists of a capsid (protein coat) that protects the transgene and determines **tropism**. cellular, that is, the vector's affinity for a specific type of cell (e.g., photoreceptor, RPE, or Müller cells).

The choice of AAV **serotype** is critical and defines the success of the therapy. Serotypes such as AAV2 were the first to be used, but demonstrated low penetration capacity into the outer retina after intravitreal injection. The development and study of new serotypes (such as AAV8, AAV9 and, more recently, synthetic variants such as AAV2/8 or AAV2/9) sought to overcome this limitation, presenting greater efficiency in transduction of target cells and lower risk.



Immunogenicity. Current research in ophthalmology focuses on the **bioengineering of capsids** to create optimized AAV vectors that, after simple intravitreal injection, can cross the inner retinal boundary and efficiently transfect photoreceptors, simplifying the surgical procedure and reducing the risks associated with subretinal injection.

The primary limitation of AAVs lies in their **carrying capacity** (approximately 4.7 kilobases). Many genes involved in DHRs, such as the *Usherin* gene (*USH2A*), are too large (giant) to be packaged into a single AAV vector, requiring *dual-vector* strategies.

(Dual vectors), where the gene is split into two halves and delivered by two distinct vectors, which recombine within the target cell. This strategy introduces complexity and inefficiency, as recombination is not 100% guaranteed. On the other hand, the *RPE65* gene, which is relatively small, fits perfectly into the AAV, which contributed to the clinical success of *Luxturna* and demonstrates the importance of gene size in the viability of classic gene replacement therapy.

4.2. Voretigene Neparvovec (*Luxturna*): The Clinical Framework and its Mechanisms

Voretigene neparvovec (trade name *Luxturna*) is the first and, to date, only gene therapy product approved for RPE65 retinal detachments (biallelic mutation of the *RPE65* gene). Its mechanism is based on the delivery of a functional copy of the *RPE65* gene encapsulated in an AAV2 vector. The vector is administered via **subretinal injection**, directly into the macular region, where the retinal detachment created by the injection allows direct access to the Retinal Pigment Epithelium (RPE). Once inside the RPE cells, the transgene (the new *RPE65*) is expressed, resulting in the production of the missing functional enzyme, allowing the restoration of the visual cycle and light sensitivity (MEHTA, 2020).

The results of Phase III studies, published by Bennett et al. (2018), demonstrated significant improvements in **light sensitivity**, as measured by the multi-luminance mobility test (MLMT), and in visual acuity in treated patients. The success of *Luxturna* not only validated the concept of gene therapy for eye diseases but also established the **subretinal procedure** as the gold standard for delivering AAV vectors to the outer retina.

However, the treatment is expensive and has limitations: it is only effective in patients who still have viable photoreceptor cells (i.e., in non-terminal stages of the disease) and is specific to the *RPE65* mutation, not being applicable to any other form of DHR.

The immune response to the AAV capsid is an inherent challenge in gene therapy. Many individuals possess pre-existing **neutralizing antibodies** against the AAV serotypes used, due to prior exposure to natural viral infections. The presence of these antibodies can neutralize the vector before it reaches the target cells, drastically reducing the effectiveness of the therapy. This necessitates pre-treatment *screening* of patients to assess antibody titers. This limitation is driving research into new *immunosuppression* strategies or the development of...

Pseudotyped or synthetic AAV vectors that are less recognized by the host's immune system, allowing for the safe treatment of a larger patient population.

5. GENOMIC EDITING WITH CRISPR-CAS9: PROMISES AND CHALLENGES IN DNA REPAIR

5.1. Mechanism of Action of CRISPR-Cas9: Precision in the Ocular Genome

CRISPR-Cas9 technology (Clustered Regularly Interspaced Short Palindromic Repeats and associated endonuclease) is a **genome editing** tool that offers an unparalleled level of molecular precision. Unlike gene replacement therapy, which adds a healthy gene, CRISPR-Cas9 allows **cutting and editing** DNA directly at the exact location of the mutation.

The system consists of an endonuclease protein (Cas9) and a guide RNA (*sgRNA*) that directs Cas9 to a specific sequence in the genome. After the double-stranded DNA is cut, the cell activates its repair mechanisms (primarily non-homologous end joining, NHEJ, or homology-directed repair, HDR), allowing scientists to insert, delete, or correct the mutation (JINEK et al., 2012).

The potential of CRISPR-Cas9 is particularly noteworthy for retinal hypersensitivity reactions (RHs) caused by **gain-of-** function mutations (autosomal dominant diseases, such as retinitis pigmentosa caused by *RHO mutations*), where the defective protein is toxic and needs to be eliminated. In these cases, therapy not only needs to silence the gene, but can also aim to correct the mutation or eliminate the defective gene. The *in vivo* approach in the retina, where the CRISPR components (Cas9 and *sgRNA*) are encapsulated in AAV vectors and injected, is the most tested strategy.

Preclinical studies have demonstrated that genome editing in the retina is feasible and can correct mutations that would lead to degeneration, proving the applicability of the tool in sensory tissues.

The first *in vivo* genome editing therapy to enter clinical trials (Phase I) for a DHR was **EDIT-101**, designed to treat Leber Congenital Amaurosis type 10 (ACL10) caused by a specific mutation in the *CEP290 gene*. CEP290 is a very large gene, and the therapy aims to correct the mutation directly within the photoreceptors. Follow-up of these patients will provide crucial data on the safety and efficacy of *in vivo* genome editing in humans. The clinical ophthalmologist needs to understand that genome editing represents the **second wave of gene therapy**, promising to expand treatment for mutations that are untreatable by simple gene replacement.



5.2. Specificity Challenges and Off-Target Effects on the Retina

The greatest technical and ethical challenge of the CRISPR-Cas9 system lies in its potential to generate **off-target effects** (unwanted cuts). The sgRNA can bind to and direct Cas9 to sequences in the genome that are similar, but not identical, to the target, resulting in mutations in unexpected locations. In the retina, where precision is crucial and cell regeneration is limited, an *off-target* cut could lead to cell death (apoptosis) or, in theory, tumor formation (neoplasia), compromising patient safety. Current research is focused on developing **high-fidelity** Cas9 systems and optimizing guide RNAs to increase editing specificity.

Beyond safety, the **efficiency of CRISPR component delivery** is complex. The combined size of the Cas9 endonuclease and sgRNA often exceeds the standard payload capacity of the most efficient AAV vectors, forcing the use of dual vectors or newer, less understood AAV vectors. Ensuring that a sufficient therapeutic dose reaches the photoreceptor nucleus without causing toxicity is a fine line that defines clinical success or failure.

The ophthalmologist must monitor not only visual function, but also the **structural integrity of the retina** (via OCT and autofluorescence) to detect any signs of toxicity induced by the vector or the CRISPR system itself.

Cellular repair after Cas9 cleavage is another control point. Non-homologous (NHEJ) repair is efficient but tends to be erroneous (inserting or deleting bases), being useful for **silencing** (destroying the gene). However, for **precise correction** (replacing a defective base), homology-directed repair (HDR) is necessary, which is much less efficient in quiescent cells such as photoreceptors. This limitation drives research into **base editing**, which uses Cas9-derived enzymes (catalytically inactive) to chemically convert one base into another (e.g., A to G) without creating a double-strand break, promising greater safety and precision for correcting point mutations.

6. Clinical Advances and the Therapeutic Window: Implications for the OPHTHALMOLOGIST

6.1. The Success of Clinical Trials and the Expansion of Genetic Targets

The success of *Luxturna* has spurred a vast portfolio of clinical trials focused on other DHR mutations. Currently, there are dozens of gene therapies in different stages of development, targeting genes such as *CHM* (for choroideremia), *RS1* (for X-linked retinoschisis), *USH2A* (for Usher syndrome type II), and the rhodopsin (*RHO*) gene in its recessive mutations (SILVA, 2021). Preliminary results from these trials consistently show...



A good safety profile and signs of stabilization or, in some cases, improvement in visual acuity and visual field, especially in patients with slower progression and in whom the intervention occurred in **early stages** of the disease. The demonstration of efficacy in multiple genotypes reinforces gene therapy as a therapeutic platform and not just as an isolated solution.

The ophthalmologist needs to be aware of the crucial nature of the **therapeutic window**. Gene therapy aims **to rescue** photoreceptor cells that are still alive but dysfunctional; it cannot **regenerate** cells that have already died. Therefore, the earlier the intervention occurs, the larger the population of viable cells to be treated and the better the visual prognosis. This necessitates **early genetic diagnosis**, ideally in childhood or adolescence, before the degeneration has progressed to terminal stages. Patient and family education about the importance of timely genotyping is now an integral part of the specialized ophthalmological consultation.

Clinical trials are providing valuable data on the **optimal vector dose**. Higher doses increase the likelihood of transduction (successful gene delivery) but also raise the risk of retinal inflammation and toxicity, which can be detected by imaging tests such as Optical Coherence Tomography (OCT). Management of post-surgical inflammation, which usually requires the use of systemic and topical corticosteroids, is a critical area of research. The ophthalmologist administering gene therapy must be proficient in **postoperative monitoring**, knowing how to differentiate between benign and expected inflammation and severe inflammation that can lead to photoreceptor loss.

6.2. Strategies to Overcome Delivery Limitations: The New Generation of Vectors

To overcome the payload capacity and immunogenicity limitations of conventional AAVs, research is investing in the **next generation of vectors**. This includes the development of synthetic (or bioengineered) AAVs with chemically modified capsids to exhibit **enhanced tropism** and lower antigenicity, allowing for efficient photoreceptor transduction after safer intravitreal injection. Furthermore, non-viral vectors (such as liposomes and lipid nanoparticles) are being explored for the delivery of mRNA and CRISPR components, as they are not limited by capsid payload capacity and can bypass pre-existing immunity to the virus.

Another area of intense research is **combined cell therapy**. Patients in advanced stages of DHRs, in whom most photoreceptors are already lost, do not benefit from salvage gene therapy. For these cases, hope lies in combining **gene therapy**.

(to provide neuroprotective or modulatory factors) with **cell replacement therapy**, using induced pluripotent stem cells (iPSCs) differentiated into RPE cells or photoreceptors. Transplantation of these replacement cells can restore retinal structure,

requiring ophthalmologists to develop proficiency in vitreoretinal surgery techniques and cell graft monitoring, which represents the future of retinal surgery.

Base editing and *prime editing* technologies represent the future of precision. As mentioned, these tools allow for the correction of point mutations (which account for the majority of DHRs) without causing double-strand DNA breakage, dramatically increasing the safety profile in sensitive tissues such as the retina. Although still in pre-clinical phases for ophthalmology, monitoring the development of these technologies is crucial. The ophthalmologist of the future will be able to offer personalized therapies, choosing the ideal molecular tool (replacement, silencing, or editing) based on the patient's specific genetic mutation.

7. Ethical, Regulatory, and Cost Implications of Precision Medicine

7.1. The Ethical Challenge and Risk Communication of Genomic Intervention

The introduction of gene therapy and genome editing in ophthalmology raises profound ethical questions that physicians must address with complete transparency. The main one lies in **risk communication**, especially regarding the *off-target* effects of CRISPR-Cas9 and the irreversibility of somatic genome editing. Informed consent must be robust and include a clear discussion of the potential risks (including the theoretical risk of neoplasia), the expected benefits (improvement in mobility and light sensitivity, but not necessarily restoration of perfect visual acuity), and the long-term uncertainties about the durability of gene expression and safety.

The issue of **equity and access** is an ethical and social challenge. Gene therapies, such as *Luxturna*, are notoriously expensive, representing a cost per eye that can be prohibitive for most global health systems and patients. Ophthalmologists, as advocates for patients, should participate in the debate on value *-based payment models*, where treatment payments are distributed over time and conditional on maintaining visual efficacy. Furthermore, there is the ethical challenge of **patient screening**, where the decision about who receives treatment (prioritizing patients with viable cells and better prognosis) must be transparent and fair, avoiding socioeconomic or geographic biases (MEHTA, 2020).

Germline editing (reproductive cells), while currently prohibited and ethically unacceptable for clinical purposes, is a subject of constant scrutiny. Somatic editing (non-reproductive cells, such as those of the retina) is accepted under strict regulatory control, as the risk is limited to the patient. However, ophthalmologists should be the first to educate the community and authorities.

Regarding the distinction between these two types of editing, ensuring that the fear of germline editing does not paralyze the crucial advances in somatic editing aimed at healing debilitating diseases.

7.2. Regulation and Long-Term Monitoring by ANVISA and FDA

The regulatory process for gene therapies and genome editing is complex, requiring unprecedented rigor and long-term monitoring. Regulatory agencies such as the FDA (USA) and ANVISA (Brazil) have established accelerated pathways for the approval of therapies for rare diseases (such as DHRs), but require extensive safety data. The follow-up protocol for patients treated with gene therapy often extends for 15 years or more to monitor the durability of gene expression, the persistence of viral vectors, and, crucially, the late emergence of toxicity or neoplasms related to vector integration (or *off-target* effects of Cas9).

Standardizing **efficacy assessment methodologies** is an ongoing regulatory challenge. Beyond traditional visual acuity (Snellen chart) and visual field tests, the success of gene therapy in people with heart failure requires more sensitive functional metrics, such as the aforementioned multi-luminance mobility test (MLMT), which assesses a patient's ability to navigate an environment with varying levels of illumination. Standardizing these tests is essential to ensure that clinical trial results are comparable and reproducible worldwide, facilitating the regulatory approval process and clinical adoption.

Ophthalmologists involved in administering these therapies must report to **national and international registries and databases** to ensure long-term surveillance. The need to track the fate and safety of each injected AAV vector batch is a regulatory requirement that ensures patient safety and the accumulation of real-world evidence that complements clinical trial data. Mastering regulatory submission processes and understanding pharmacovigilance and genomics policies are new responsibilities for the ophthalmologist of the future.

8. CONCLUSION

The incursion of **gene therapy** and **genome editing** into the field of ophthalmology represents the most significant advance in the treatment of hereditary blindness since the invention of cataract surgery. The retina, as an ideal model for genetic intervention, has validated the concept that incurable monogenic diseases can be transformed into treatable conditions, offering real hope to millions of patients. The success of voretigene neparvovec (*Luxturna*) in treating the *RPE65* mutation has demonstrated the efficacy of gene replacement and established **adeno-associated viral vectors (AAVs)** as the gold standard for the safe delivery of the material.

In vivo genetic testing . This first wave of gene replacement therapies is now expanding to dozens of other DHR genotypes, requiring ophthalmologists to integrate **genetic diagnosis** as a mandatory and early step in clinical evaluation.

The emergence of **genome editing with CRISPR-Cas9** signals the next therapeutic frontier, promising to address **gain-of-function** mutations and others that are untreatable by simple replacement. The potential for precise DNA correction at its native location is enormous, but it comes with critical safety and ethical challenges. The issue of **off-target effects** and the need for more efficient delivery systems (bioengineered AAVs or nanoparticles) are the focus of current research. Collaboration between ophthalmologists, geneticists, and bioengineers is essential to refine the technology and ensure that molecular precision is accompanied by maximum safety and clinical efficacy, with rigorous monitoring of post-injection retinal integrity becoming the new standard of surveillance.

In this scenario, the role of ophthalmologist Roberto Paione Gasparini transcends traditional clinical practice, requiring proficiency in **translational medicine and genetic counseling**. The physician must be the link between molecular complexity and the patient's hope, communicating risks and benefits clearly, especially regarding the ideal **therapeutic window** . Early intervention, while viable photoreceptor cells are still present, is the most important prognostic factor, reinforcing the urgency of timely *screening* and genotyping in children and adolescents diagnosed with DHRs.

The challenges of **access and equity** in the treatment of human drug disorders are inseparable from scientific advances. The high cost of gene therapies necessitates an ethical and regulatory debate on value-based funding models that ensure innovations save vision and do not merely become accessible to an elite. Standardization of efficacy metrics (beyond visual acuity) and long-term surveillance (for more than a decade) are regulatory requirements that demonstrate the seriousness of the commitment to the safety and durability of these genomic interventions.

In short, ophthalmology, driven by genomics, is at the forefront of the precision medicine revolution. The future promises not only disease stabilization but also a **cure** or reversal of vision loss. Research will continue to focus on overcoming vector delivery limitations, improving CRISPR fidelity, and exploring combined (gene and cell) therapies for advanced stages of the disease. Mastering these principles is the new frontier for ophthalmologists who aspire to offer the most advanced vision care.

It is emphatically concluded that gene therapy and genome editing are not just a research topic, but a **clinical reality** being incorporated into the therapeutic arsenal of ophthalmology. Success in this area demonstrates the power of basic science in solving problems.

chronic clinical cases, establishing a new standard of excellence and hope in the treatment of hereditary retinal dystrophies.

REFERENCES

BENNETT, Jean. et al. Safety and Efficacy of Voretigene Neparvovec in Children and Adults with Leber Congenital Amaurosis Due to RPE65 Mutations. **The Lancet**, vol. 390, n. 10094, p. 849-860, 2017.

JINEK, Martin. et al. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. **Science**, vol. 337, no. 6096, p. 816-821, 2012.

MEHTA, BP Gene Therapy in Ophthalmology: Current Status and Future Perspectives. **Current Opinion in Ophthalmology**, vol. 31, no. 5, p. 382-389, 2020.

NAGEL, JD The Ethics of Genome Editing in Ocular Disease. **Molecular Therapy**, vol. 28, no. 1, p. 7-10, 2020.

SILVA, AC Translational Research in Gene Therapy for Inherited Retinal Diseases. **Journal of Ocular Pharmacology and Therapeutics**, vol. 37, no. 1, p. 28-36, 2021.

STONE, Edwin M. Genetic Testing for Inherited Eye Diseases. **Progress in Retinal and Eye Research**, vol. 35, p. 115-132, 2013.

TANG, LI Advances in the Development of Next-Generation Adeno-Associated Virus Vectors for Retinal Gene Therapy. **Vision Research**, vol. 182, p. 1-12, 2021.

VERNON, SA Inherited Retinal Diseases: From Molecular Mechanisms to Therapeutic Options. **Survey of Ophthalmology**, vol. 66, no. 6, p. 942-959, 2021.